PELI3 Antibody (N-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q8N2H9 |
---|---|
Clone Names | 100406097 |
Gene ID | 246330 |
---|---|
Other Names | E3 ubiquitin-protein ligase pellino homolog 3, Pellino-3, 632-, PELI3 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP13453a was selected from the N-term region of PELI3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | PELI3 (HGNC:30010) |
---|---|
Function | E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins (PubMed:12874243, PubMed:17675297). Involved in the TLR and IL-1 signaling pathways via interaction with the complex containing IRAK kinases and TRAF6 (PubMed:12874243). Mediates 'Lys-63'-linked polyubiquitination of IRAK1 (PubMed:12874243). Can activate AP1/JUN and ELK1 (PubMed:12874243). Acts as a regulator of innate immunity by mediating 'Lys-63'-linked polyubiquitination of RIPK2 downstream of NOD1 and NOD2, thereby transforming RIPK2 into a scaffolding protein for downstream effectors, ultimately leading to activation of the NF-kappa-B and MAP kinases signaling (By similarity). Catalyzes 'Lys-63'-linked polyubiquitination of RIPK2 in parallel of XIAP (By similarity). |
Tissue Location | Highly expressed in brain, heart and testis, and at lower level in kidney, liver, lung, placenta, small intestine, spleen and stomach. Isoform 1 is not expressed in lung |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Toll-like receptors (TLRs; see MIM 603030) and IL1R(IL1R1; MIM 147810) are part of the innate immune response aimed atmobilizing defense mechanisms in response in infection or injury.Pellino proteins, such as PELI3, are intermediate components in thesignaling cascades initiated by TLRs and IL1R (Jensen andWhitehead, 2003 [PubMed 12874243]).
References
Xiao, H., et al. J. Biol. Chem. 283(21):14654-14664(2008)Butler, M.P., et al. J. Biol. Chem. 280(30):27759-27768(2005)Jensen, L.E., et al. J. Immunol. 171(3):1500-1506(2003)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.